Navigation Links
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
Date:8/5/2009

dates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma or to achieve market acceptance for such treatments, the possibility that priority review will not be granted by the FDA for the pixantrone NDA and that a decision by the FDA is not rendered in late 2009, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling OPAXIO, pixantrone, and brostallicin, and the risk factors listed or described from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, we do not intend to update or alter our forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: deramian@ctiseattle.com
    www.celltherapeutics.com/media.htm

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
   http://www.celltherapeutics.com/investors

                              Cell Therapeutics, Inc.

                  Condensed Consolidated Statements of Operations
                   (In thousands, except for per share amounts)
                                    (unaudited)

                              Three Months Ended       Six Months Ended
                                    June 30,                June 30,
                                    --------                --------
                                2009        
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Shenzhen ... – Beike Biotechnology, the world,s largest stem ... derived mesenchymal stem cell packets containing no less ... new product could significantly reduce the time and ... in the case of degenerative conditions such ...
(Date:5/6/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. ... cancers, today announced that Linda Powers , NW Bio CEO, ... vaccine platform for solid tumor cancers and the Company,s multiple ...   , , , DATE: , , , ... , , , 12:15 PM EDT , , , ...
(Date:5/6/2015)... Dr Jaspreet Singh , Senior Research Officer from ... the 2015 Asian Starch Conference, to be held ... , As an honored ... Starch: A Potential Source for the Creation of Next ... a 528 page text book entitled "Advances in Potato ...
(Date:5/5/2015)... 5, 2015 Roka Bioscience, Inc. (NASDAQ: ROKA ... solutions for the detection of foodborne pathogens,  today announced that ... of America Merrill Lynch 2015 Health Care Conference on May ... Encore at the Wynn, Las Vegas NV. ... will be available through the investor relations section of Roka ...
Breaking Biology Technology:Beike Biotechnology Produces High-dose Adult Stem Cell Packets for Degenerative Conditions 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2
... Traits to Improve Farmer ... ... Biotechnology Co., Ltd. (BWK) today announced the,formation of a joint venture ... as stress tolerance and efficient nutrient,utilization to improve the performance of ...
... December 10, 2007, SPACE COAST, Fla., Dec. ... Third Annual Colloquium on the Law of,Transbeman Persons, ... held December 10, 2007 along Florida,s Space Coast. ... and computerized,substrate., The colloquia are open to ...
... and GAITHERSBURG, Md., Nov. 30 Binex,(KOSDAQ: 053030) ... a,Sponsored Research Agreement to evaluate MaxCyte,s GMP-compliant cell,loading ... cancer immunotherapies. Upon completion of the research studies,the ... technology for,clinical and commercial use in Korea. Financial ...
Cached Biology Technology:DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts 2DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts 3International Human Rights Day Recognized by Terasem Movement, Inc.'s Third Annual Colloquium on the Law of Transbeman Persons 2Binex and MaxCyte Collaborate on Cancer Immunotherapy Research 2
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... chairman of Singapore A*STAR,s Biomedical Research Council, has received ... cancer research through his discovery of p53 tumour suppressor ... one of the highest accolades from the Royal Society ... endeavour have made an impact on people,s lives worldwide. ...
... ionising radiation with ever better methods sci-entists have ... age. In addition to natural radiation, mankind is exposed ... result from the military and technical use of radioactive ... medical applications, it is necessary to determine even the ...
... Sept. 16, 2008 Researchers at UT ... improve electrical stimulation of nerves by outfitting electrodes ... coating of basic black, formed from carbon nanotubes. ... and transmitted by electrodes, which researchers say is ...
Cached Biology News:Radioactivity: Discover the lowest amounts with new methods 2Radioactivity: Discover the lowest amounts with new methods 3Coating improves electrical stimulation therapy used for Parkinson's, depression, chronic pain 2
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... serum is collected off the clot from fasted Cynomolgus ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA ... N-07: CPD N-09: K3EDTA ...
adult...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: